Montelukast Actavis 4mg. 5mg & 10mg

Actavis Ireland is pleased to announce the introduction of Montelukast Paediatric (4 mg and 5 mg) and Montelukast Actavis (10 mg) on the first day of patent expiry.

Delivering key products on Day One continues to be an important focus for Actavis Ireland and this latest launch - on 25th February - continues to underline Actavis’ position as the fastest growing pharmaceutical company on the Irish market¹.

Indicated for the treatment of asthma, Montelukast Paediatric is available in 4 mg and 5 mg x 28 chewable tablets and Montelukast Actavis 10mg, for adolescents and adults from 15 years of age, is available in packs of 28 film coated tablets. Subject to medical prescription, Montelukast is GMS reimbursable and available from all wholesalers from February 25th.

Montelukast Paediatric 4 mg is available at a trade price of €18.27 and the 5 mg at €18.71. Montelukast Actavis 10 mg has a trade price of €18.38.

Notes: ¹ IMS December 2012